Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper
The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Increased orexin/hypocretin signaling is implicated in opioid withdrawal, sleep disturbances, and drug-seeking behaviors. This study examined whether a dual-orexin receptor antagonist would improve sleep and withdrawal outcomes when compared with placebo during a buprenorphine/naloxone taper. In two-group comparisons, participants receiving suvorexant displayed increased total sleep time (TST) during the buprenorphine/naloxone taper and decreased Subjective Opiate Withdrawal Scale (SOWS) during the post-taper period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 2×
“In hierarchical regression models, the effect of suvorexant was significant when subtracting the relationship between TST and Avoidance or Control (P < 0.05) but not Wanting (table S1). pression Rating Scale (HAM-D) were not different between participants receiving suvorexant and those receiving placebo at discharge […”
MethodInfluentialThe consensus sleep diary: standardizing prospective sleep self-monitoring
Carney, C. E., Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Krystal, A. D., Lichstein, K. L., & Morin, C. M. (2012) · Sleep · doi:10.5665/sleep.1642 · Cited by 2,172
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Chung, F., Abdullah, H. R., & Liao, P. (2016) · Chest · doi:10.1378/chest.15-0903 · Cited by 1,362 · cited 1×
“Participants were ineligible if they were seeking or currently enrolled in maintenance treatment for OUD; were pregnant or breast feeding; showed evidence of physical dependence on alcohol or benzodiazepines that required medical detoxification; had a known allergy to the study medications; reported past 30-day prescr…”
MethodA role for lateral hypothalamic orexin neurons in reward seeking
Harris, G. C., Wimmer, M., & Aston-Jones, G. (2005) · Nature · doi:10.1038/nature04071 · Cited by 1,311
The Clinical Opiate Withdrawal Scale (COWS)
Wesson, D. R., & Ling, W. (2003) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2003.10400007 · Cited by 1,120
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703
Two New Rating Scales for Opiate Withdrawal
Handelsman, L., Cochrane, K. J., Aronson, M. J., Ness, R., Rubinstein, K. J., & Kanof, P. D. (1987) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998709001515 · Cited by 599
Michelson, D., Snyder, E., Paradis, E., Chengan-Liu, M., Snavely, D. B., Hutzelmann, J., Walsh, J. K., Krystal, A. D., Benca, R. M., Cohn, M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70053-5 · Cited by 519
Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal
Georgescu, D., Zachariou, V., Barrot, M., Mieda, M., Willie, J. T., Eisch, A. J., Yanagisawa, M., Nestler, E. J., & DiLeone, R. J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03106.2003 · Cited by 373
Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant
Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., Lines, C., Roth, T., & Michelson, D. (2012) · Neurology · doi:10.1212/wnl.0b013e31827688ee · Cited by 322
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
Herring, W. J., Connor, K. M., Ivgy-May, N., Snyder, E., Liu, K., Snavely, D. B., Krystal, A. D., Walsh, J. K., Benca, R. M., Rosenberg, R., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.003 · Cited by 300
Columbia-Suicide Severity Rating Scale
Posner, K. (2016) · PsycTESTS Dataset · doi:10.1037/t52667-000 · Cited by 199
Orexin/hypocretin role in reward: implications for opioid and other addictions
Baimel, C., Bartlett, S. E., Chiou, L., Lawrence, A. J., Muschamp, J. W., Patkar, O., Tung, L., & Borgland, S. L. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12639 · Cited by 179
Levendowski, D. J., Ferini‐Strambi, L., Gamaldo, C. E., Cetel, M. B., Rosenberg, R., & Westbrook, P. R. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6618 · Cited by 178
Self-citationDiscontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176
Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL Initiative
Collins, F. S., Koroshetz, W. J., & Volkow, N. D. (2018) · JAMA · doi:10.1001/jama.2018.8826 · Cited by 161
Thannickal, T. C., John, J., Shan, L., Swaab, D. F., Wu, M.-F., Ramanathan, L., McGregor, R., Chew, K.-T., Cornford, M., Yamanaka, A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4953 · Cited by 138
Zhou, Y., Bendor, J., Hofmann, L., Randesi, M., Ho, A., & Kreek, M. J. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06960 · Cited by 127
Role of orexin/hypocretin in dependence and addiction
Sharf, R., Sarhan, M., & Dileone, R. (2009) · Brain Research · doi:10.1016/j.brainres.2009.08.028 · Cited by 117
Bidirectional Relationship between Opioids and Disrupted Sleep: Putative Mechanisms
Eacret, D., Veasey, S. C., & Blendy, J. A. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.119107 · Cited by 102
Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone
Antoine, D., Huhn, A. S., Strain, E. C., Turner, G., Jardot, J., Hammond, A. S., & Dunn, K. E. (2021) · The American Journal on Addictions · doi:10.1111/ajad.13069 · Cited by 94
Self-citationXu, K. Y., Hartz, S. M., Borodovsky, J. T., Bierut, L. J., & Grucza, R. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.28557 · Cited by 94
Effects of orexin receptor antagonism on human sleep architecture: A systematic review
Clark, J. W., Brian, M. L., Drummond, S. P. A., Hoyer, D., & Jacobson, L. H. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101332 · Cited by 89
Snyder, E., Ma, J., Svetnik, V., Connor, K. M., Lines, C., Michelson, D., & Herring, W. J. (2015) · Sleep Medicine · doi:10.1016/j.sleep.2015.10.007 · Cited by 79
Orexin Signaling in the VTA Gates Morphine-Induced Synaptic Plasticity
Baimel, C., & Borgland, S. L. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4385-14.2015 · Cited by 73
Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.
Huhn, A. S., & Finan, P. H. (2022) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000477 · Cited by 65
Self-citationSchwarzer, A., Aichinger-Hinterhofer, M., Maier, C., Vollert, J., & Walther, J. W. (2015) · Pain · doi:10.1097/j.pain.0000000000000279 · Cited by 56
Efficacy of Tramadol Extended-Release for Opioid Withdrawal
Dunn, K. E., Tompkins, D. A., Bigelow, G. E., & Strain, E. C. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1838 · Cited by 51
Self-citationHuhn, A. S., Sweeney, M. M., Brooner, R. K., KIDORF, M. S., Tompkins, D. A., Ayaz, H., & Dunn, K. E. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0252-0 · Cited by 50
Self-citationBoyett, B., Wiest, K. L., McLeod, L., Nelson, L. M., Bickel, W. K., Learned, S. M., Heidbreder, C. A., Fudala, P. J., Moigne, A. L., & Zhao, Y. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109057 · Cited by 45
Schoedel, K. A., Sun, H., Sellers, E. M., Faulknor, J., Levy‐Cooperman, N., Li, X., Kennedy, W. P., Cha, J., Lewis, N. M., Liu, W., et al. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000516 · Cited by 43
Ahmadi‐Soleimani, S. M., Ghaemi-Jandabi, M., Azizi, H., & Semnanian, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.10.064 · Cited by 39
Esmaili‐Shahzade‐Ali‐Akbari, P., Hosseinzadeh, H., & Mehri, S. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.02.005 · Cited by 37
Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone
Tompkins, D. A., Lanier, R. K., Harrison, J. A., Strain, E. C., & Bigelow, G. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1838-3 · Cited by 33
Self-citationActigraphy combined with EEG compared to polysomnography in sleep apnea patients
Fietze, I., Penzel, T., Partinen, M., Sauter, J., Küchler, G., Suvoro, A., & Hein, H. (2015) · Physiological Measurement · doi:10.1088/0967-3334/36/3/385 · Cited by 33
Sleep Profile in Opioid Dependence: A Polysomnographic Case–Control Study
Mehtry, V., Nizamie, S. H., Parvez, N., & Pradhan, N. (2014) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0000000000000117 · Cited by 32
Zarepour, L., Fatahi, Z., Sarihi, A., & Haghparast, A. (2014) · Neuropeptides · doi:10.1016/j.npep.2014.04.003 · Cited by 30
Dunn, K. E., Bergeria, C. L., Huhn, A. S., & Strain, E. C. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108212 · Cited by 24
Self-citationO’Connor, S. L., Fragale, J. E. C., James, M. H., & Aston‐Jones, G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.25.061887 · Cited by 16
Dunn, K. E., Finan, P. H., Huhn, A. S., Gamaldo, C. E., Bergeria, C. L., & Strain, E. C. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000483 · Cited by 16
Self-citationAlteration of orexin-A and PKCα in the postmortem brain of pure-opioid and multi-drug abusers
Sadat‐Shirazi, M., Soltani, H., Nikpour, N., Haghshenas, M., Khalifeh, S., Mokri, A., & Zarrindast, M. (2020) · Neuropeptides · doi:10.1016/j.npep.2020.102074 · Cited by 11
Moving Beyond Medications That Act at the μ Receptor in the Treatment of Opioid Use Disorder
Strain, E. C., Kampman, K. M., & Weiss, R. D. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0259 · Cited by 9
Self-citation
Cited by
The orexin story and orexin receptor antagonists for the treatment of insomnia
Muehlan, C., Roch, C., Vaillant, C., & Dingemanse, J. (2023) · Journal of Sleep Research · doi:10.1111/jsr.13902 · Cited by 137
“Results are remarkable in that suvorexant was well tolerated and improved TST, self-reported opioid-use withdrawal symptoms, and craving (Huhn et al., 2022).”
BackgroundMogavero, M. P., Silvani, A., Lanza, G., DelRosso, L. M., Ferini‐Strambi, L., & Ferri, R. (2023) · Nature and Science of Sleep · doi:10.2147/nss.s201994 · Cited by 70
“Lastly, suvorexant was recently found to ameliorate sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper, suggesting that it might be a promising treatment for sleep and opioid withdrawal.(182) On the other hand, drug abuse, which encompasses the use of prescription drugs for purposes other t…”
Ten-Blanco, M., Flores, Á., Cristino, L., Pereda-Pérez, I., & Berrendero, F. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101066 · Cited by 50
“disturbances and opioid withdrawal and craving (Huhn et al., 2022).”
Kukkonen, J. P., Jacobson, L. H., Hoyer, D., Rinne, M. K., & Borgland, S. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000953 · Cited by 36
Giannotti, G., Mottarlini, F., Heinsbroek, J. A., Mandel, M. R., James, M. H., & Peters, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02161-z · Cited by 26
“Indeed, initial preclinical studies indicate that DORAs reduce drug taking and seeking across several classes of drugs of abuse [47–50], and a preliminary clinical study reported that the DORA suvorexant (marketed by Merck as Belsomra) reduces several relapse-related and self-reported craving indices in patients with…”
Background
Metadata
- Authors
- Huhn, A. S., Finan, P. H., Gamaldo, C. E., Hammond, A. S., Umbricht, A., Bergeria, C. L., Strain, E. C., & Dunn, K. E.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Huhn, Andrew S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2022-06-22
- Volume
- 14
- Issue
- 650
- Pages
- eabn8238-eabn8238
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4283275984
- Cited by
- 79
- References
- 45
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 28 · 2023: 16 · 2022: 4
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (UG3DA048734)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- suvorexant, orexin receptor antagonists, opioid use disorder, opioid withdrawal, sleep disorders, total sleep time, opioid craving, abuse liability
- MeSH terms
- Analgesics, Opioid, Azepines, Buprenorphine, Double-Blind Method, Humans, Naloxone, Narcotic Antagonists, Sleep, Substance Withdrawal Syndrome, Triazoles, Treatment Outcome, Opiate Substitution Treatment, Craving
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.